Skip to main content
Top
Published in: Supportive Care in Cancer 10/2011

01-10-2011 | Original Article

Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network

Authors: Edwin Pun Hui, Linda K. S. Leung, Terence C. W. Poon, Frankie Mo, Vicky T. C. Chan, Ada T. W. Ma, Annette Poon, Eugenie K. Hui, So-shan Mak, Maria Lai, Kenny I. K. Lei, Brigette B. Y. Ma, Tony S. K. Mok, Winnie Yeo, Benny C. Y. Zee, Anthony T. C. Chan

Published in: Supportive Care in Cancer | Issue 10/2011

Login to get access

Abstract

Purpose

We aimed to validate the Multinational Association for Supportive Care in Cancer (MASCC) risk index, and compare it with the Talcott model and artificial neural network (ANN) in predicting the outcome of febrile neutropenia in a Chinese population.

Methods

We prospectively enrolled adult cancer patients who developed febrile neutropenia after chemotherapy and risk classified them according to MASCC score and Talcott model. ANN models were constructed and temporally validated in prospectively collected cohorts.

Results

From October 2005 to February 2008, 227 consecutive patients were enrolled. Serious medical complications occurred in 22% of patients and 4% died. The positive predictive value of low risk prediction was 86% (95% CI = 81–90%) for MASCC score ≥ 21, 84% (79–89%) for Talcott model, and 85% (78–93%) for the best ANN model. The sensitivity, specificity, negative predictive value, and misclassification rate were 81%, 60%, 52%, and 24%, respectively, for MASCC score ≥ 21; and 50%, 72%, 33%, and 44%, respectively, for Talcott model; and 84%, 60%, 58%, and 22%, respectively, for ANN model. The area under the receiver-operating characteristic curve was 0.808 (95% CI = 0.717–0.899) for MASCC, 0.573 (0.455–0.691) for Talcott, and 0.737 (0.633–0.841) for ANN model. In the low risk group identified by MASCC score ≥ 21 (70% of all patients), 12.5% developed complications and 1.9% died, compared with 43.3%, and 9.0%, respectively, in the high risk group (p < 0.0001).

Conclusions

The MASCC risk index is prospectively validated in a Chinese population. It demonstrates a better overall performance than the Talcott model and is equivalent to ANN model.
Literature
1.
go back to reference Anaissie EJ, Vadhan-Raj S (1995) Is it time to redefine the management of febrile neutropenia in cancer patients? Am J Med 98:221–223PubMedCrossRef Anaissie EJ, Vadhan-Raj S (1995) Is it time to redefine the management of febrile neutropenia in cancer patients? Am J Med 98:221–223PubMedCrossRef
2.
go back to reference Baskaran ND, Gan GG, Adeeba K (2008) Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol 87:563–569PubMedCrossRef Baskaran ND, Gan GG, Adeeba K (2008) Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol 87:563–569PubMedCrossRef
3.
go back to reference Baxt WG (1995) Application of artificial neural networks to clinical medicine. Lancet 346:1135–1138PubMedCrossRef Baxt WG (1995) Application of artificial neural networks to clinical medicine. Lancet 346:1135–1138PubMedCrossRef
4.
go back to reference Bottaci L, Drew PJ, Hartley JE, Hadfield MB, Farouk R, Lee PW, Macintyre IM, Duthie GS, Monson JR (1997) Artificial neural networks applied to outcome prediction for colorectal cancer patients in separate institutions. Lancet 350:469–472PubMedCrossRef Bottaci L, Drew PJ, Hartley JE, Hadfield MB, Farouk R, Lee PW, Macintyre IM, Duthie GS, Monson JR (1997) Artificial neural networks applied to outcome prediction for colorectal cancer patients in separate institutions. Lancet 350:469–472PubMedCrossRef
5.
go back to reference Bryce TJ, Dewhirst MW, Floyd CE Jr, Hars V, Brizel DM (1998) Artificial neural network model of survival in patients treated with irradiation with and without concurrent chemotherapy for advanced carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 41:339–345PubMedCrossRef Bryce TJ, Dewhirst MW, Floyd CE Jr, Hars V, Brizel DM (1998) Artificial neural network model of survival in patients treated with irradiation with and without concurrent chemotherapy for advanced carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 41:339–345PubMedCrossRef
6.
go back to reference Cherif H, Johansson E, Bjorkholm M, Kalin M (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91:215–222PubMed Cherif H, Johansson E, Bjorkholm M, Kalin M (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91:215–222PubMed
8.
9.
go back to reference Das A, Ben-Menachem T, Cooper GS, Chak A, Sivak MV Jr, Gonet JA, Wong RC (2003) Prediction of outcome in acute lower-gastrointestinal haemorrhage based on an artificial neural network: internal and external validation of a predictive model. Lancet 362:1261–1266PubMedCrossRef Das A, Ben-Menachem T, Cooper GS, Chak A, Sivak MV Jr, Gonet JA, Wong RC (2003) Prediction of outcome in acute lower-gastrointestinal haemorrhage based on an artificial neural network: internal and external validation of a predictive model. Lancet 362:1261–1266PubMedCrossRef
10.
go back to reference Das A, Ben-Menachem T, Farooq FT, Cooper GS, Chak A, Sivak MV Jr, Wong RC (2008) Artificial neural network as a predictive instrument in patients with acute nonvariceal upper gastrointestinal hemorrhage. Gastroenterology 134:65–74PubMedCrossRef Das A, Ben-Menachem T, Farooq FT, Cooper GS, Chak A, Sivak MV Jr, Wong RC (2008) Artificial neural network as a predictive instrument in patients with acute nonvariceal upper gastrointestinal hemorrhage. Gastroenterology 134:65–74PubMedCrossRef
11.
go back to reference de Bont ES, Vellenga E, Swaanenburg JC, Fidler V, Visser-van Brummen PJ, Kamps WA (1999) Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol 107:375–380PubMedCrossRef de Bont ES, Vellenga E, Swaanenburg JC, Fidler V, Visser-van Brummen PJ, Kamps WA (1999) Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol 107:375–380PubMedCrossRef
12.
go back to reference de Souza Viana L, Serufo JC, da Costa Rocha MO, Costa RN, Duarte RC (2008) Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 16:841–846PubMedCrossRef de Souza Viana L, Serufo JC, da Costa Rocha MO, Costa RN, Duarte RC (2008) Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 16:841–846PubMedCrossRef
13.
go back to reference Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Avritscher EB, Shih YC, Ensor J, Bekele BN, Gralla RJ, Talcott JA, Rolston K (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606–611PubMedCrossRef Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Avritscher EB, Shih YC, Ensor J, Bekele BN, Gralla RJ, Talcott JA, Rolston K (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606–611PubMedCrossRef
14.
go back to reference Finberg RW, Talcott JA (1999) Fever and neutropenia—how to use a new treatment strategy. N Engl J Med 341:362–363PubMedCrossRef Finberg RW, Talcott JA (1999) Fever and neutropenia—how to use a new treatment strategy. N Engl J Med 341:362–363PubMedCrossRef
15.
go back to reference Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, Giamarellou H (2001) Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 32:1718–1725PubMedCrossRef Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, Giamarellou H (2001) Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 32:1718–1725PubMedCrossRef
16.
go back to reference Jimeno A, Garcia-Velasco A, del Val O, Gonzalez-Billalabeitia E, Hernando S, Hernandez R, Sanchez-Munoz A, Lopez-Martin A, Duran I, Robles L, Cortes-Funes H, Paz-Ares L (2004) Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 100:2462–2469PubMedCrossRef Jimeno A, Garcia-Velasco A, del Val O, Gonzalez-Billalabeitia E, Hernando S, Hernandez R, Sanchez-Munoz A, Lopez-Martin A, Duran I, Robles L, Cortes-Funes H, Paz-Ares L (2004) Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 100:2462–2469PubMedCrossRef
17.
go back to reference Kern WV (2006) Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis 42:533–540PubMedCrossRef Kern WV (2006) Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis 42:533–540PubMedCrossRef
18.
go back to reference Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129–4134PubMedCrossRef Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129–4134PubMedCrossRef
19.
go back to reference Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed
20.
go back to reference Ma B, Yeo W, Hui P, Ho WM, Johnson PJ (2002) Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer—a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 62:185–189PubMedCrossRef Ma B, Yeo W, Hui P, Ho WM, Johnson PJ (2002) Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer—a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 62:185–189PubMedCrossRef
21.
go back to reference Oude Nijhuis CS, Daenen SM, Vellenga E, van der Graaf WT, Gietema JA, Groen HJ, Kamps WA, de Bont ES (2002) Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. Crit Rev Oncol Hematol 44:163–174PubMedCrossRef Oude Nijhuis CS, Daenen SM, Vellenga E, van der Graaf WT, Gietema JA, Groen HJ, Kamps WA, de Bont ES (2002) Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. Crit Rev Oncol Hematol 44:163–174PubMedCrossRef
22.
go back to reference Paesmans M, Rapoport B, Maertens J, Slabber C, Ferrant A, Wingard J, Aoun M, Dubreucq L, Plehiers B, Klastersky J (2003) Multicentric prospective validation of the mascc risk-index score for identification of febrile neutropenic cancer patients at low-risk for serious medical complications. Proc Am Soc Clin Oncol 22:556, abstr 2235 Paesmans M, Rapoport B, Maertens J, Slabber C, Ferrant A, Wingard J, Aoun M, Dubreucq L, Plehiers B, Klastersky J (2003) Multicentric prospective validation of the mascc risk-index score for identification of febrile neutropenic cancer patients at low-risk for serious medical complications. Proc Am Soc Clin Oncol 22:556, abstr 2235
23.
go back to reference Poon TC, Chan AT, Zee B, Ho SK, Mok TS, Leung TW, Johnson PJ (2001) Application of classification tree and neural network algorithms to the identification of serological liver marker profiles for the diagnosis of hepatocellular carcinoma. Oncology 61:275–283PubMedCrossRef Poon TC, Chan AT, Zee B, Ho SK, Mok TS, Leung TW, Johnson PJ (2001) Application of classification tree and neural network algorithms to the identification of serological liver marker profiles for the diagnosis of hepatocellular carcinoma. Oncology 61:275–283PubMedCrossRef
24.
go back to reference Poon TC, Yip TT, Chan AT, Yip C, Yip V, Mok TS, Lee CC, Leung TW, Ho SK, Johnson PJ (2003) Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 49:752–760PubMedCrossRef Poon TC, Yip TT, Chan AT, Yip C, Yip V, Mok TS, Lee CC, Leung TW, Ho SK, Johnson PJ (2003) Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 49:752–760PubMedCrossRef
25.
go back to reference Ramilo O, Allman W, Chung W, Mejias A, Ardura M, Glaser C, Wittkowski KM, Piqueras B, Banchereau J, Palucka AK, Chaussabel D (2007) Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 109:2066–2077PubMedCrossRef Ramilo O, Allman W, Chung W, Mejias A, Ardura M, Glaser C, Wittkowski KM, Piqueras B, Banchereau J, Palucka AK, Chaussabel D (2007) Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 109:2066–2077PubMedCrossRef
26.
go back to reference Sargent DJ (2001) Comparison of artificial neural networks with other statistical approaches: results from medical data sets. Cancer 91:1636–1642PubMedCrossRef Sargent DJ (2001) Comparison of artificial neural networks with other statistical approaches: results from medical data sets. Cancer 91:1636–1642PubMedCrossRef
27.
go back to reference Schwarzer G, Vach W, Schumacher M (2000) On the misuses of artificial neural networks for prognostic and diagnostic classification in oncology. Stat Med 19:541–561PubMedCrossRef Schwarzer G, Vach W, Schumacher M (2000) On the misuses of artificial neural networks for prognostic and diagnostic classification in oncology. Stat Med 19:541–561PubMedCrossRef
28.
go back to reference Talcott JA, Finberg R, Mayer RJ, Goldman L (1988) The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148:2561–2568PubMedCrossRef Talcott JA, Finberg R, Mayer RJ, Goldman L (1988) The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148:2561–2568PubMedCrossRef
29.
go back to reference Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMed Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMed
30.
go back to reference Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R (1994) Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107–114PubMed Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R (1994) Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107–114PubMed
31.
go back to reference Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560PubMedCrossRef Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560PubMedCrossRef
32.
go back to reference Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R (2007) Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care (Engl) 16:475–483CrossRef Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R (2007) Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care (Engl) 16:475–483CrossRef
33.
go back to reference Uzun O, Anaissie EJ (1999) Outpatient therapy for febrile neutropenia: who, when, and how? J Antimicrob Chemother 43:317–320PubMedCrossRef Uzun O, Anaissie EJ (1999) Outpatient therapy for febrile neutropenia: who, when, and how? J Antimicrob Chemother 43:317–320PubMedCrossRef
Metadata
Title
Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network
Authors
Edwin Pun Hui
Linda K. S. Leung
Terence C. W. Poon
Frankie Mo
Vicky T. C. Chan
Ada T. W. Ma
Annette Poon
Eugenie K. Hui
So-shan Mak
Maria Lai
Kenny I. K. Lei
Brigette B. Y. Ma
Tony S. K. Mok
Winnie Yeo
Benny C. Y. Zee
Anthony T. C. Chan
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 10/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0993-8

Other articles of this Issue 10/2011

Supportive Care in Cancer 10/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine